Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1982 2
1983 1
1985 1
1986 4
1987 10
1988 10
1989 9
1990 16
1991 16
1992 14
1993 22
1994 23
1995 22
1996 37
1997 27
1998 29
1999 34
2000 44
2001 31
2002 37
2003 41
2004 44
2005 41
2006 33
2007 34
2008 33
2009 37
2010 29
2011 24
2012 34
2013 32
2014 30
2015 18
2016 20
2017 14
2018 16
2019 20
2020 19
2021 25
2022 10
2023 8
2024 6
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

912 results

Results by year

Filters applied: . Clear all
Page 1
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. Eisenhauer EA, et al. Among authors: verweij j. Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. Eur J Cancer. 2009. PMID: 19097774
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Judson I, et al. Among authors: verweij j. Lancet Oncol. 2014 Apr;15(4):415-23. doi: 10.1016/S1470-2045(14)70063-4. Epub 2014 Mar 5. Lancet Oncol. 2014. PMID: 24618336 Clinical Trial.
Mitomycin C.
Verweij J, Pinedo HM. Verweij J, et al. Cancer Chemother Biol Response Modif. 1991;12:59-65. Cancer Chemother Biol Response Modif. 1991. PMID: 1931457 Review. No abstract available.
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PC, Ouali M, Marreaud S, Bramwell VH, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Woll PJ, et al. Among authors: verweij j. Lancet Oncol. 2012 Oct;13(10):1045-54. doi: 10.1016/S1470-2045(12)70346-7. Epub 2012 Sep 4. Lancet Oncol. 2012. PMID: 22954508 Clinical Trial.
Aurora kinase inhibitors.
Kitzen JJ, de Jonge MJ, Verweij J. Kitzen JJ, et al. Among authors: verweij j. Crit Rev Oncol Hematol. 2010 Feb;73(2):99-110. doi: 10.1016/j.critrevonc.2009.03.009. Epub 2009 Apr 14. Crit Rev Oncol Hematol. 2010. PMID: 19369091 Review.
Epidemiological and Clinical Insights into the Enterovirus D68 Upsurge in Europe 2021-2022 and Emergence of Novel B3-Derived Lineages, ENPEN Multicentre Study.
Simoes MP, Hodcroft EB, Simmonds P, Albert J, Alidjinou EK, Ambert-Balay K, Andrés C, Antón A, Auvray C, Bailly JL, Baldanti F, Bastings C, Beard S, Berengua C, Berginc N, Bloemen M, Blomqvist S, Bosma F, Böttcher S, Bubba L, Buderus S, Cabrerizo M, Calvo C, Celma C, Ceriotti F, Clark G, Costa I, Coste-Burel M, Couderé K, Cremer J, Del Cuerpo Casas M, Daehne T, de Beer J, de Ceano-Vivas M, De Gascun C, de Rougemont A, Dean J, Dembinski JL, Diedrich S, Diez-Domingo J, Dillner L, Dorenberg DH, Ducancelle A, Dudman S, Dyrdak R, Eis-Huebinger AM, Falces-Romero I, Farkas A, Feeney S, Fernandez-Garcia MD, Flipse J, Franck KT, Galli C, Garrigue I, Geeraedts F, Georgieva I, Giardina F, Guiomar R, Hauzenberger E, Heikens E, Henquell C, Hober D, Hönemann M, Howson-Wells H, Hruškar Ž, Ikonen N, Imbert B, Jansz AR, Jeannoël M, Jiřincová H, Josset L, Keeren K, Kramer-Lindhout N, Krokstad S, Lazrek M, Le Guillou-Guillemette H, Lefeuvre C, Lind A, Lunar MM, Maier M, Marque-Juillet S, McClure CP, McKenna J, Meijer A, Menasalvas Ruiz A, Mengual-Chuliá B, Midgley S, Mirand A, Molenkamp R, Montes M, Moreno-Docón A, Morley U, Murk JL, Navascués-Ortega A, Nijhuis R, Nikolaeva-Glomb L, Nordbø SA, Numan… See abstract for full author list ➔ Simoes MP, et al. Among authors: verweij jj. J Infect Dis. 2024 Oct 16;230(4):e917-e928. doi: 10.1093/infdis/jiae154. J Infect Dis. 2024. PMID: 38547499 Free PMC article.
The epothilone dilemma.
de Jonge M, Verweij J. de Jonge M, et al. Among authors: verweij j. J Clin Oncol. 2005 Dec 20;23(36):9048-50. doi: 10.1200/JCO.2005.03.8844. Epub 2005 Nov 21. J Clin Oncol. 2005. PMID: 16301592 No abstract available.
[Unexpected recurrence of malaria].
Beugelink L, Gast KB, Verweij JJ, van Wijngaarden P. Beugelink L, et al. Among authors: verweij jj. Ned Tijdschr Geneeskd. 2021 May 27;165:D5302. Ned Tijdschr Geneeskd. 2021. PMID: 34346585 Dutch.
Innovation in oncology clinical trial design.
Verweij J, Hendriks HR, Zwierzina H; Cancer Drug Development Forum. Verweij J, et al. Cancer Treat Rev. 2019 Mar;74:15-20. doi: 10.1016/j.ctrv.2019.01.001. Epub 2019 Jan 4. Cancer Treat Rev. 2019. PMID: 30665053 Review.
912 results